NASDAQ: GANXGain Therapeutics Inc Stock
$1.80+0.06 (+3.45%)
Updated Apr 17, 2025
GANX Price
$1.80
Fair Value Price
$0.44
Market Cap
$50.02M
52 Week Low
$0.89
52 Week High
$3.65
P/E
-2.02x
P/B
6.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.65
Operating Cash Flow
-$19M
Beta
1.06
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GANX Overview
Gain Therapeutics, Inc., a biotechnology company, develops treatments for rare genetic diseases and neurological disorders caused by protein misfolding. Using its Site-Directed Enzyme Enhancement Therapy platform, the company discovers allosteric sites on misfolded proteins and identifies proprietary small molecules that bind to these sites, restore protein folding, and treating diseases such as Morquio B disease, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe disease, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, MD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GANX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GANX
Ranked#293 of 463
Ranked#293 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important GANX news, forecast changes, insider trades & much more!
GANX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GANX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GANX ($1.80) is overvalued by 304.93% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GANX ($1.80) is not significantly undervalued (304.93%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GANX due diligence checks available for Premium users.
Valuation
GANX fair value
Fair Value of GANX stock based on Discounted Cash Flow (DCF)
Price
$1.80
Fair Value
$0.44
Overvalued by
304.93%
GANX ($1.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GANX ($1.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GANX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.02x
Industry
-177.72x
Market
27.98x
GANX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.81x
Industry
4.05x
GANX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GANX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
GANX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.1M
Liabilities
$4.8M
Debt to equity
0.65
GANX's short-term assets ($11.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GANX's short-term assets ($11.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GANX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GANX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$43.4k
Financing
$2.3M
GANX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GANX vs Biotech Stocks
Gain Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.